Management of rare forms of lymphoma

Current Opinion in Oncology

Volumn 10, Issue 5, 1998, Pages 377-384

  Zucca, Emanuele ^a   Bertoni, Francesco ^a   Roggero, Enrico ^a   Cavalli, Franco ^a  

^a OSPEDALE SAN GIOVANNI   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; HUMAN; LYMPHOMA; MANTLE CELL LYMPHOMA; MEDIASTINUM LYMPH NODE; MONOCYTE; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; REVIEW; T CELL LYMPHOMA; WHOLE BODY RADIATION;

EID: 15144359412     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199809000-00002     Document Type: Review

References (76)

1. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink HK, Pileri SA, Piris MA, Ralfkiaer E, Waroke, RA: A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994, 84:1361-1392.
2. The Non-Hodgkin's Lymphoma Classification Project: A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997, 89:3909-3918. A series of 1403 consecutive patients from nine institutions in eight different countries was the subject of histopathologic review and survival analysis. This important study is the first clinical validation of the REAL classification, demonstrating that it allows easy, accurate, and reproducible identification of clinically distinctive lymphoma subtypes.
3. Grogan TM, Miller TP, Fisher RJ: A Southwest Oncology Group perspective on the Revised European-American Lymphoma classification. Hematol Oncol Clin North Am 1997, 11:819-846.
4. Fisher RI, Dahlberg S, Nathwani BN, et al.: A clinical analysis of two indolent lymphoma entities: Mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue lymphoma and monocytoid B-cell subcategories) a Southwest Oncology Group study. Blood 1995, 85:1075-1082.
5. Horning SJ: Purine analogues in marginal-zone lymphomas. Ann Oncol 1996, 7(suppl. 6):S21-S26.
6. Zucca E, Roggero E, Pileri S: B-cell lymphoma of MALT type: a review with special emphasis on diagnostic and management problems of low-grade tumours. Br J Haematol 1998, 100:2-14.
7. Roggero E, Zucca E, Pinotti G, Pascarella A, Capella C, Savio A, Pedrinis E, Paterlini A, Venco A, Cavalli F: Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosa-associated lymphoid tissue. Ann Intern Med 1995, 122:767-769.
8. Bayerdorffer E, Neubauer A, Rudolph B, Thiede C, Lehn N, Eidt S, Stolte M: Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. Lancet 1995, 345:1591-1594.
9. Neubauer A, Thiede C, Morgner A, Alpen B, Ritter M, Neubauer B, Wundisch T, Ehninger G, Stolte M, Bayerdorffer E: Cure of Helicobacter pylori infection and duration of remission of low-grade gastric MALT lymphoma. J Natl Cancer Inst 1997, 89:1350-1355.
10. Pinotti G, Zucca E, Roggero E, Pascarella A, Bertoni F, Savio A, Savio E, Capella C, Pedrinis E, Saletti P, Morandi E, Santandrea G, Cavalli F: Clinical features, treatment and outcome in a series of 93 patients with low-grade gastric MALT lymphoma. Leuk Lymphoma 1997, 26:527-537.
11. Roggero E, Zucca E, Cavalli F: Gastric mucosa-associated lymphoid tissue lymphomas: more than a fascinating model. J Natl Cancer Inst 1997, 89:1328-1330.
12. Sackmann M, Morgner A, Rudolph B, Neubauer A, Thiede C, Schulz H, Kraemer W, Boersch G, Ronde P, Seifert E, Stolte M, Bayerdoerffer E: Regression of gastric MALT lymphoma after eradication of Helicobacter pylori is predicted by endosonographic staging. MALT Lymphoma Study Group. Gastroenterology 1997, 113:1087-1090.
13. De Jong D, Boot H, van Herdee P, Hart AAM, Taal BG: Histological grading in gastric lymphoma: pretreatment criteria and clinical relevance. Gastroenterology 1997, 112:1466-1474.
14. Cerroni L, Signoretti S, Hofler G, Annessi G, Putz B, Lackinger E, Metze D, Giannetti A, Kerl H: Primary cutaneous marginal zone B-cell lymphoma: a recently described entity of low-grade malignant cutaneous B-cell lymphoma. Am J Surg Pathol 1997, 21:1307-1315.
15. Isaacson PG, Piris MA: Splenic marginal zone lymphoma. Adv Anat Pathol 1997, 4:191-201.
16. Dierlamm J, Pittaluga S, Wlodarska I, Stul M, Thomas J, Boogaerts M, Michaux L, Driessen A, Mecucci C, Cassiman JJ, De Wolf-Peeters C, Van den Berghe H: Marginal zone B-cell lymphomas of different sites share similar cytogenetic and morphologic features. Blood 1996, 87:299-307.
17. De Wolf-Peeters C, Pittaluga S, Dierlamm J, Wlodarska I, van den Berghe H: Marginal zone-B-cell lymphomas including mucosa-associated lymphoid tissue type lymphoma (MALT), monocytoid B-cell lymphoma and splenic marginal zone cell lymphoma and their relation to the reactive marginal zone. Leuk Lymphoma 1997, 26:467-478.
18. Murakami H, Irisawa H, Saitoh T, Matsushima T, Tamura J, Sawamura M, Karasawa M, Hosomura Y, Kojima M: Immunological abnormalities in splenic marginal zone cell lymphoma. Am J Hematol 1997, 56:173-178.
19. Troussard X, Valensi F, Duchayne E, Garand R, Felman P, Tulliez M, Henry-Amar M, Bryon PA, Flandrin G: Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Groupe Francais d'Hematologie Cellulaire (GFHC). Br J Haematol 1996, 93:731-736.
20. Bolam S, Orchard J, Oscier D: Fludarabine is effective in the treatment of splenic lymphoma with villous lymphocytes. Br J Haematol 1997, 99:158-161.
21. Weisenburger DD, Armitage JO: Mantle cell lymphoma: an entity comes of age. Blood 1996, 87:4483-4494.
22. Zucca E, Roggero E, Pinotti G, Pedrinis E, Cappella C, Venco A, Cavalli F: Patterns of survival in mantle cell lymphoma. Ann Oncol 1995, 6:257-262.
23. Meusers P, Hense J, Brittinger G: Mantle cell lymphoma: diagnostic criteria, clinical aspects and therapeutic problems. Leukemia 1997, 11 (suppl 20):S60-S64.
24. Coiffier B: Which treatment for mantle-cell lymphoma patients in 1998? J Clin Oncol 1998, 16:3-5.
25. Bosch F, Lopez-Guillermo A, Campo E, Ribera JM, Conde E, Piris MA, Vallespi T, Woessner S, Montserrat E: Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer 1998, 82:567-575.
26. Teodorovic I, Pittaluga S, Kluin-Nelemans JC, Meerwaldt JH, Hagenbeek A, van Glabbeke M, Somers R, Bijnens L, Noordijk EM, Peeters CD: Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1995, 13:2819-2826.
27. Younes A, Ayoub JP, Sarris A, Hagemeister F, North L, Pate O, McLaughlin P, Alma Rodriguez M, Romaguera J, Kurrock R, Preti A, Bachier C, Smith T, Cabanillas F: Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: Final report of a phase II trial. Br J Haematol 1997, 96:328-332.
28. Decaudin D, Bosq J, Tertian G, Nedellec G, Bennaceur A, Venuat AM, Bayle C, Carde P, Bendahmane B, Hayat M, Munck JN: Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas. J Clin Oncol 1998, 16:579-583.
29. Dreger P, Von Neuhoff N, Kuse R, Sonnen R, Glass B, Uharek L, Bartels H, Loffler H, Schmitz N: Sequential high-dose therapy and autologous stem cell transplantation for treatment of mantle cell lymphoma. Ann Oncol 1997, 8:401-403.
30. Corradini P, Astolfi M, Cherasco C, Ladetto M, Voena C, Caracciolo D, Pileri A, Tarella C: Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. Blood 1997, 89:724-731.
31. Corradini P, Ladetto M, Astolfi M, Voena C, Tarella C, Bacigalupo A, Pileri A: Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma. Br J Haematol 1996, 94:376-378.
32. Haas R, Brittinger G, Meusers P, Murea S, Goldschmidt H, Wannenmacher M, Hunstein W: Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma. Leukemia 1996, 10:1975-1979.
33. Ketterer N, Salles G, Espinouse D, Dumontet C, Neidhardt-Berard EM, Moullet I, Bouafia F, Berger F, Felman P, Coiffier B: Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma. Ann Oncol 1997, 8:701-704.
34. Gressin R, Legouffe E, Leroux D, Jacob MC, Swiercz P, Peoch M, Capdevilla V, Rossi JF, Thyss A, Sotto JJ: Treatment of mantle-cell lymphomas with the VAD ± chlorambucil regimen with or without subsequent high-dose therapy and peripheral blood stem-cell transplantation. Ann Oncol 1997, 8(suppl 1):S103-S106.
35. Andersen NS, Donovan JW, Borus JS, Poor CM, Neuberg D, Aster JC, Nadler LM, Freedman AS, Gribben JG: Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood 1997, 90:4212-4221.
36. Freedman AS, Neuberg D, Gribben JG, Mauch P, Soiffer RJ, Fisher DC, Anderson KC, Anderson N, Schlossman R, Kroon M, Ritz J, Aster J, Nadler LM: High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol 1998, 16:13-18.
37. McLaughlin P, Seymour J, Fuller L, Cabanillas F: Combined modality therapy for stage I-II MALT lymphoma and mantle cell lymphoma. Ann Oncol 1996, 7:211-212.
38. Vanderberghe E, De Wolf-Peeters, Vaughan Hudson G, Vaughan Hudson B, Pittaluga S, Anderson L, Linch DC: The clinical outcome of 65 cases of mantle cell lymphoma initially treated with non-intensive therapy by the British National Lymphoma Investigation Group. Br J Haematol 1997, 99:842-847.
39. Joos S, Otano-Joos MJ, Ziegler S, Bruderlein S, du Manoir S, Bentz M, Moller P, Lichter P: Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood 1996, 87:1571-1578.
40. Jaffe E: Histopathology of the non-Hodgkin's lymphoma and Hodgkin's disease. In The lymphomas. Edited by Canellos GP, Lister TA, Sklar JL. Philadelphia: WB Saunders; 1998: 77-106.
41. Bishop PC, Wilson WH, Janik J, Little R, Pearson D, Jaffe ES, Elwood PC: CNS involvement in primary mediastinal (thymic) large B-cell lymphoma [abstract]. Blood 1997, 90(suppl. 1):252b.
42. Lazzarino M, Orlandi E, Paulli M, Strater J, Klersy C, Gianelli U, Gargantini L, Rousset MT, Gambacorta M, Marra E, Lavabre-Bertrand T, Magrini U, Manegold C, Bernasconi C, Moller P: Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: a multicenter study of 106 patients. J Clin Oncol 1997, 15:1646-1653.
43. Cazals Hatem D, Lepage E, Brice P, Ferrant A, D'Agay MF, Baumelou E, Briere J, Blanc M, Gaulard P, Biron P, Schlaifer D, Diebold J, Audouin JTI: Primary mediastinal large B-Cell lymphoma: A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA ('Groupe d'Etude des Lymphomes de l'Adulte') study. Am J Surg Pathol 1996, 20:877-888.
44. Popat U, Przepiork D, Champlin R, Pugh W, Amin K, Mehra R, Rodriguez J, Giralt S, Romaguera J, Rodriguez A, Preti A, Andersson B, Khouri I, Claxton D, de Lima M, Donato M, Anderlini P, Gajewski J, Cabanillas F, van Besien K: High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome. J Clin Oncol 1998, 16:63-69.
45. Sehn LH, Antin JH, Shulman LN, Mauch P, Elias A, Kadin ME, Wheeler C: Primary diffuse large B-cell lymphoma of the mediastinum: outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation. Blood 1998, 91:717-723.
46. Armitage JO: Peripheral T-cell lymphoma. In The Lymphomas. Edited by Canellos GP, Lister TA, Sklar JL. Philadelphia: WB Saunders; 1998: 439-448.
47. Grogan TM: Immunohistochemistry of lymphomas. In The Lymphomas. Edited by Canellos GP, Lister TA, Sklar JL. Philadelphia: WB Saunders; 1998: 151-183.
48. Jaffe ES, Krenacs L, Raffeld M: Classification of T-cell and NK-cell neoplasms based on the REAL classification, Ann Oncol 1997, 8(suppl 2):S17-S24.
49. Melnyk A, Rodriguez A, Pugh WC, Cabannillas F: Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood 1997, 89:4514-4520.
50. Gascoyne RD: Pathologic prognostic factors in diffuse aggressive non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 1997, 11:847-863.
51. Karakas T, Bergmann L, Stutte HJ, Jager E, Knuth A, Weidmann E, Mitrou PS, Hoelzer D: Peripheral T-cell lymphomas respond well to vincristine, adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) and have a similar outcome as high-grade B-cell lymphomas. Leuk Lymphoma 1996, 24:121-129.
52. Delmer A, Zittoun RA: Other peripheral T-cell lymphomas. In The Non-Hodgkin's Lymphomas, ed. 2. Edited by Magrath IT. London: Arnold, 1997:927-954.
53. Jaffe ES, Chan JKC, Su IJ, Frizzera G, Mori S, Feller AC, Ho FCD: Report of the workshop on nasal and related extranodal angiocentric T/Natural Killer cell lymphomas. Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 1996, 20:103-111.
54. Cavalli F: Extranodal lymphomas. In The Non-Hodgkin's Lymphomas, ed. 2. Edited by Magrath IT. London: Arnold, 1997: 1007-1027.
55. Abbondanzo SL, Wenig BM: Non-Hodgkin's lymphoma of the sinonasal tract. A clinicopathologic and immunophenotypic study of 120 cases. Cancer 1995, 75:1281-1291.
56. Van de Rijn M, Bhargava V, Molma-Kirsch H, Carlos-Bregni R, Warnke RA, Cleary ML, Kamel OW: Extranodal head and neck lymphomas in Guatemala: high frequency of Epstein-Barr virus-associated sinonasal lymphomas. Hum Pathol 1997, 28:834-839.
57. Logsdon MD, Ha CS, Kavadi, Cabanillas F, Hess MA, Cox JD: Lymphoma of the nasal cavity and paranasal sinuses: improved outcome and altered prognostic factors with combined modality therapy. Cancer 1997, 80:477-488.
58. Hausdorff J, Davis E, Long G, Hoppe R, van der Pas M, Lassman C, Kamel O, Jacobs C: Non-Hodgkin's lymphoma of the paranasal sinuses: clinical and pathological features, and response to combined-modality therapy. Cancer J Sci Am 1997, 3:303-311.
59. Cheung MM, Chan JK, Lau WH, Foo W, Chan PT, Ng CS, Ngan RK: Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 1998, 16:70-77.
60. Jaffe ES: Angioimmunoblastic T-cell lymphoma: new insights, but the clinical challenge remains. Ann Oncol 1995, 6:631-632.
61. Advani R, Warnke R, Sikic BI, Horning S: Treatment of angioimmunoblastic T-cell lymphoma with cyclosporine. Ann Oncol 1997, 8:601-603.
62. Sallah AS, Bernard S: Treatment of angioimmunoblastic lymphadenopathy with dysproteinemia using 2-chlorodeoxyadenosine. Ann Hematol 1996, 73:295-296.
63. Siegert W, Nerl C, Agthe A, Engelhard M, Brittinger G, Tiemann M, Lennert K, Huhn D: Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma: prognostic impact of clinical observation and laboratory findings at presentation. Ann Oncol 1995, 6:659-664.
64. Cooke CB, Krenacs L, Stetler-Stevenson M, Greiner TC, Raffeld M, Kingma DW, Abruzzo L, Frantz C, Kaviani M, Jaffe ES: Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic γδ T-cell origin. Blood 1996, 88:4265-4274.
65. Reyes F, Belhadj K, Tilly H, Charlotte F, Leblond V, Duval C, Angonin R, Deconinck E, Tulliez M, Perot C, Pico JL, Zafrani ES, Farcet JP, Gaulard P: Hepatosplenic γδ T-cell lymphoma: a recently recognized entity which is fatal [abstract]. Blood 1997, 90(suppl. 1):338a.
66. Salhany KE, Feldman M, Kahn MJ, Peritt D, Schretzenmair RD, Wilson DM, DiPaola RS, Glick AD, Kant JA, Nowell PC, Kamoun M: Hepatosplenic gd T-cell lymphoma: ultrastructural, immunophenotypic, and functional evidence for cytotoxic T lymphocyte differentiation. Hum Pathol 1997, 28:674-685.
67. Sallah S, Smith SV, Lony LCL, Woodard P, Schmitz JL, Folds JD: Gamma/delta T-cell hepatosplenic lymphoma: Review of the literature, diagnosis by flow cytometry and concomitant autoimmune hemolytic anemia. Ann Hematol 1997, 74:139-142.
68. Arnulf B, Copie-Bergman C, Delfau-Larue MH, Lavergne-Slove A, Bosq J, Wechsler J, Wassef M, Matuchansky C, Epardeau B, Stern M, Bagot M, Reyes F, Gaulard P: Nonhepatosplenic gammadelta t-cell lymphoma: a subset of cytotoxic lymphomas with mucosal or skin localization. Blood 1998, 91:1723-1731.
69. Sandlund JT, Pui CH, Roberts WM, Santan VM, Morris SW, Berard CW, Hutchinson RE, Ribeiro R, Mahmoud H, Crist WM, Rafferty M, Raimond SC: Clinicopathologic features and treatment outcome of children with large cell lymphoma and the t(2;5) (p23;q35). Blood 1994, 84:2467-2471.
70. Shiota M, Nakamura S, Ichinohasama R, Abe M, Akagi T, Takeshita M, Mori N, Fujimoto J, Miyauchi A, Mikatta A, Nanba K, Takami T, Yamabe H, Takano Y, Izumo T, Nagatani T, Mohri N, Nasu K, Satoh H, Katano H, Fujimoto J, Yamamoto T: Anaplastic large cell lymphomas expressing the novel chimeric protein p80 NPM/ALK: A distinct clinicopathologic entity. Blood 1995, 85:1954-1960.
71. Pittaluga S, Wlodarska I, Pulford K, Campo E, Morris SW, Van den Berghe H, De Wolf-Peeters Cb: The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements. Am J Pathol 1997, 151:343-351.
72. Kim YH, Hoppe RT: Cutaneous T-cell lymphomas. In The non-Hodgkin's lymphomas, ed. 2. Edited by Magrath IT. London: Arnold, 1997: 907-926.
73. Willemze R, Kerl H, Sterry W, Berti E, Cerroni L, Chimenti S, Diaz-Perez JL, Geers ML, Goos M, Knobler R, Ralfkiaer E, Santucci M, Smith N, Wechsler J, van Vloten WA, Meijer CJLM: EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997, 90:354-371. This paper describes the basic principles of a recent proposal for the classification of primary cutaneous lymphomas, as well as the clinical, histopathologic, immunologic, and genetic features of the different entitites. Moreover, survival analysis of a large series of 626 patients illustrates the clinical utility of this new classification.
74. Domizio P, Owen RA, Sheperd NA, Talbot IC, Norton AJ: Primary lymphoma of the small intestine: a clinicopathologic study of 119 cases. Am J Surg Pathol 1993, 17:429-442.
75. Salem PA, Jones DV: Treatment of malignant neoplasms of the mucosa associated lymphoid tissue. In The non-Hodgkin's lymphomas, ed. 2. Edited by Magrath IT. London: Arnold 1997; 1007-1027.
76. Zucca E, Roggero E, Bertoni F, Cavalli F: Primary extranodal non-Hodgkin's lymphomas. Part 1: gastrointestinal, cutaneous and genitourinary lymphomas. Ann Oncol 1997, 8:727-737.